BOSTON, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that data from microbiology testing of omadacycline will be presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy/International Congress of Chemotherapy and Infection. Known as ICAAC/ICC2015, the conference will be held September 17 – 21 in San Diego, California. Omadacycline is a once-daily oral and intravenous, broad-spectrum antibiotic currently in clinical development.
"There is an urgent need for new antibiotics to address the growing challenge of resistance," said Evan Loh, M.D., President and Chief Medical Officer, Paratek Pharmaceuticals. "The breadth of omadacycline data being presented at ICAAC in September reinforces the potential of this compound to be an important treatment option in the hospital and community setting. We look forward to sharing this information with the treatment and scientific communities."
Omadacycline presentations at ICAAC/ICC2015 include:
|
Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014) |
|
Abstract #: Poster session 088 |
|
Presenter: R. K. Flamm |
|
Session Title: New Drugs against Gram Negatives: In Vitro Activity and Insights |
|
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m. |
|
|
|
Activity of Omadacycline Tested Against Staphylococcus aureus from a Global Surveillance Program (2014) |
|
Abstract #: Poster Session 019 |
|
Presenter: R. K. Flamm |
|
Session Title: New Agents and Approaches Addressing Gram-Positive Pathogens including Mycobacteria |
|
Date and Time: Friday, September 18, 2015; 12:00 p.m. – 2:00 p.m. |
|
|
|
Activity of Omadacycline Tested Against Streptococcus pneumoniae from a Global Surveillance Program (2014) |
|
Abstract #: Poster Session 085 |
|
Presenter: R. K. Flamm |
|
Session Title: In Vitro Activities of New Drugs and Inhibitors against Gram-Positives |
|
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m. |
|
|
|
In Vitro Activity of Omadacycline Against Legionella pneumophila |
|
Abstract #: Poster Session 097 |
|
Presenter: J. Dubois |
|
Session Title: Protein Synthesis Inhibitors |
|
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m. |
|
|
|
Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Tests of Omadacycline (formerly PTK-0796) Against B. fragilis ATCC 25285, B. thetaiotaomicron ATCC 29741, E. lentum ATCC 43055 and C. difficile ATCC 700057 Using Fresh Media |
|
Abstract #: Poster session 013 |
|
Presenter: M. M. Traczewski |
|
Session Title: Antimicrobial Susceptibility Testing Methods and Interpretation for Gram-Negative Pathogens |
|
Date and Time: Friday, September 18, 2015; 12:00 p.m. – 2:00 p.m. |
|
|
|
Quality Control Limits for Broth Microdilution Susceptibility Tests of Omadacycline (formerly PTK-0796) against E. coli ATCC 25922, S. aureus ATCC 29213, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619 and H. influenza ATCC 49247 Using Fresh Media |
|
Abstract #: Poster session 163 |
|
Presenter: M. M. Traczewski |
|
Session Title: Clinical Antibacterial Susceptibility Testing and Surveillance |
|
Date and Time: Sunday, September 20, 2015; 11:00 a.m. – 1:00 p.m. |
|
|
|
The Correlation of Disk Diffusion and Broth Microdilution MIC Testing of Omadacycline |
|
Abstract #: Poster session 013 |
|
Presenter: M. M. Traczewski |
|
Session Title: Antimicrobial Susceptibility Testing Methods and Interpretation for Gram-Negative Pathogens |
|
Date and Time: Friday, September 18, 2015; 12:00 p.m. – 2:00 p.m. |
About Paratek
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is an aminomethylcycline, derived from tetracyclines. Paratek initiated a Phase 3 registration study in ABSSSI in June to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for CABP with omadacycline is planned to be initiated before the end of 2015.
Omadacycline is a new once-daily oral and intravenous, broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second product candidate, sarecycline, also known as WC 3035, is a new once-daily oral tetracycline-derived compound, designed to provide both a narrow-spectrum of antibiotic activity and favorable tolerability profile, for the treatment of acne and rosacea in the community setting. Paratek has licensed rights to sarecycline for the treatment of acne in the United States to a subsidiary of Allergan, formerly Warner Chilcott, while retaining rights in the rest of the world. Allergan is responsible for the clinical development of sarecycline for the treatment of acne in the United States. A Phase 3 program was initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.
For more information, visit www.paratekpharm.com.
Forward Looking Statements
The statements in this press release regarding the expected timing of the second Phase 3 registration trial in CABP with omadacycline and the expected benefits of Paratek's product candidates are forward-looking statements. These forward-looking statements are based upon Paratek's current expectations and involve substantial risks and uncertainties. Paratek may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in these forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to (i) the need for substantial additional funding to complete the development and commercialization of product candidates, (ii) risks that data to date and trends may not be predictive of future results, (iii) risks related to the conduct of Paratek's clinical trials, and (iv) risks that Paratek's clinical trials and product candidates do not receive regulatory approval on the time frames anticipated, or at all. These and other risk factors are discussed under "Risk Factors" and elsewhere in Paratek's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, and Paratek's other filings with the Securities and Exchange Commission. Paratek expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein.
CONTACT: Media Relations:
Michael Lampe
(484) 575-5040
michael@michaellampeconsulting.com
Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
